Details for New Drug Application (NDA): 006317
✉ Email this page to a colleague
NDA 006317 describes SULFONAMIDES DUPLEX, which is a drug marketed by Lilly and is included in one NDA. Additional details are available on the SULFONAMIDES DUPLEX profile page.
The generic ingredient in SULFONAMIDES DUPLEX is sulfadiazine; sulfamerazine. There are nineteen drug master file entries for this compound. Additional details are available on the sulfadiazine; sulfamerazine profile page.
The generic ingredient in SULFONAMIDES DUPLEX is sulfadiazine; sulfamerazine. There are nineteen drug master file entries for this compound. Additional details are available on the sulfadiazine; sulfamerazine profile page.
Summary for 006317
| Tradename: | SULFONAMIDES DUPLEX |
| Applicant: | Lilly |
| Ingredient: | sulfadiazine; sulfamerazine |
| Patents: | 0 |
Profile for product number 007
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | 250MG/5ML;250MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 011
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 167MG;167MG;167MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 012
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | 167MG/5ML;167MG/5ML;167MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
